Last reviewed · How we verify

Florbetapir F 18 PET Scan

Eli Lilly and Company · Phase 2 active Small molecule

Florbetapir F 18 PET Scan is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 2 development. Also known as: LY3078786, Amyvid.

At a glance

Generic nameFlorbetapir F 18 PET Scan
Also known asLY3078786, Amyvid
SponsorEli Lilly and Company
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Florbetapir F 18 PET Scan

What is Florbetapir F 18 PET Scan?

Florbetapir F 18 PET Scan is a Small molecule drug developed by Eli Lilly and Company.

Who makes Florbetapir F 18 PET Scan?

Florbetapir F 18 PET Scan is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is Florbetapir F 18 PET Scan also known as anything else?

Florbetapir F 18 PET Scan is also known as LY3078786, Amyvid.

What development phase is Florbetapir F 18 PET Scan in?

Florbetapir F 18 PET Scan is in Phase 2.

Related